PROF - Profound Medical Corp.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.02
-0.80 (-6.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close12.82
Open12.99
Bid11.00 x 1300
Ask17.50 x 800
Day's Range11.90 - 12.99
52 Week Range0.38 - 20.60
Volume49,497
Avg. Volume68,720
Market Cap190.733M
Beta (5Y Monthly)2.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Profound Medical Annual and Special Meeting of Shareholders Voting Results

      Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”). All of the matters put forward before the shareholders, as set out in the Company’s management information circular dated April 13, 2020 (the “Information Circular”), were approved by the requisite majority of votes cast at the Meeting. At the meeting, the shareholders of the Company elected all seven nominees for the board of directors (the “Board”).

    • Analysts Are Upgrading Profound Medical Corp. (TSE:PRN) After Its Latest Results
      Simply Wall St.

      Analysts Are Upgrading Profound Medical Corp. (TSE:PRN) After Its Latest Results

      A week ago, Profound Medical Corp. (TSE:PRN) came out with a strong set of first-quarter numbers that could...

    • GlobeNewswire

      Profound Medical Announces First Quarter 2020 Financial Results

      TORONTO, May 07, 2020 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which.

    • Has Profile Systems & Software A.E.'s (ATH:PROF) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
      Simply Wall St.

      Has Profile Systems & Software A.E.'s (ATH:PROF) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

      Profile Systems & Software A.E (ATH:PROF) has had a great run on the share market with its stock up by a significant...

    • GlobeNewswire

      Profound Medical to Release First Quarter 2020 Financial Results on May 7 – Conference Call to Follow

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its first quarter 2020 financial results after market close on Thursday, May 7, 2020. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

    • Profound Medical Corp.'s (TSE:PRN) Profit Outlook
      Simply Wall St.

      Profound Medical Corp.'s (TSE:PRN) Profit Outlook

      Profound Medical Corp.'s (TSE:PRN): Profound Medical Corp. operates as a medical technology company focuses on magnetic...

    • GlobeNewswire

      Profound Medical Announces Fourth Quarter and Full Year 2019 Financial Results

      TORONTO, March 03, 2020 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable,.

    • Here’s What Profile Systems & Software A.E.’s (ATH:PROF) Return On Capital Can Tell Us
      Simply Wall St.

      Here’s What Profile Systems & Software A.E.’s (ATH:PROF) Return On Capital Can Tell Us

      Today we'll evaluate Profile Systems & Software A.E. (ATH:PROF) to determine whether it could have potential as an...

    • GlobeNewswire

      Profound Medical Participate in March Investor Healthcare Conferences

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will participate in two investor conferences in March. Cowen and Company's 40th Annual Health Care Conference: Profound is scheduled to present on March 4, 2020 at 10:40 a.m. Eastern Time at the Boston Marriott Copley Place hotel. The presentation will be broadcast live and archived on the Company's website at www.profoundmedical.com under "Webcasts" in the Investors section.

    • GlobeNewswire

      Profound Medical to Release Fourth Quarter and Full Year 2019 Financial Results on March 3 – Conference Call to Follow

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its fourth quarter and full year 2019 financial results after market close on Tuesday, March 3, 2020. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

    • GlobeNewswire

      Profound Medical Retires Bank Debt Ahead of Schedule

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced that it has retired its $12.5 million in principal amount loan with Canadian Imperial Bank of Commerce (“CIBC”), maturing on July 29, 2022. Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.

    • GlobeNewswire

      Profound Medical Announces Closing of Offering

      Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”) at a price of US$11.65 per Common Share. The underwriters elected to exercise the over-allotment option in full, resulting in an aggregate of 3,392,500 Common Shares being issued today for aggregate gross proceeds of approximately US$40 million. Cowen acted as the sole book-running manager for the Offering.

    • Should You Be Tempted To Sell Profile Systems & Software A.E. (ATH:PROF) Because Of Its P/E Ratio?
      Simply Wall St.

      Should You Be Tempted To Sell Profile Systems & Software A.E. (ATH:PROF) Because Of Its P/E Ratio?

      This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...

    • GlobeNewswire

      Profound Medical Announces Pricing of Offering of Common Shares

      Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,950,000 common shares of the Company (the “Common Shares”), at a price of US$11.65 per Common Share (the “Offering Price”). The aggregate gross proceeds to the Company are expected to be US$34.4 million. The Company has also granted the underwriters an over-allotment option to purchase up to an additional 442,500 Common Shares at the Offering Price, exercisable in whole or in part at any time up to 30 days from the closing.

    • GlobeNewswire

      Profound Medical Announces Proposed Offering of Common Shares

      Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated October 17, 2019 (the “Base Shelf Prospectus”) in the United States and Canada relating to a proposed marketed public offering of common shares (“Common Shares”) of the Company (the “Offering”). The Offering will be priced in the context of the market with such price and the total size of the Offering to be determined at the time of entering into an underwriting agreement with respect thereto.

    • Announcing: Profound Medical (TSE:PRN) Stock Increased An Energizing 101% In The Last Year
      Simply Wall St.

      Announcing: Profound Medical (TSE:PRN) Stock Increased An Energizing 101% In The Last Year

      When you buy shares in a company, there is always a risk that the price drops to zero. On the other hand, if you find...

    • GlobeNewswire

      Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Revenues & Provides TULSA-PRO® U.S. Commercialization Update

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2019, and provided an update on the early progress it is making with the commercialization of TULSA-PRO® in the United States. Profound anticipates total revenues for the fourth quarter of 2019 to be approximately $2.7 million, representing growth of 59% year-over-year and 296% sequentially over the previous quarter.

    • GlobeNewswire

      Profound Medical and RadNet Sign the First-Ever U.S. Multi-Center Commercial Agreement for TULSA-PRO®

      Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced the signing of its first-ever U.S. multi-site imaging center agreement for TULSA-PRO® with RadNet, Inc. (RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 340 owned and/or operated outpatient imaging centers. TULSA-PRO® is a transurethral prostate tissue ablation system that combines real-time MRI with robotically-driven directional thermal ultrasound and closed-loop temperature feedback control software to deliver predictable physician prescribed ablation of whole-gland or partial prostate tissue.

    • Is Profound Medical Corp.'s (TSE:PRN) CEO Paid Enough Relative To Peers?
      Simply Wall St.

      Is Profound Medical Corp.'s (TSE:PRN) CEO Paid Enough Relative To Peers?

      In 2016 Arun Menawat was appointed CEO of Profound Medical Corp. (TSE:PRN). This report will, first, examine the CEO...

    • Investors Who Bought Profile Systems & Software A.E (ATH:PROF) Shares Three Years Ago Are Now Up 739%
      Simply Wall St.

      Investors Who Bought Profile Systems & Software A.E (ATH:PROF) Shares Three Years Ago Are Now Up 739%

      Investing can be hard but the potential fo an individual stock to pay off big time inspires us. Not every pick can be...

    • Who Has Been Buying Profound Medical Corp. (TSE:PRN) Shares?
      Simply Wall St.

      Who Has Been Buying Profound Medical Corp. (TSE:PRN) Shares?

      It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

    • GlobeNewswire

      Profound to Participate in November Investor Healthcare Conferences

      Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will participate in two investor conferences in November. Canaccord Genuity 13th Annual Medical Technologies & Diagnostics Forum: Profound is scheduled to present on November 21, 2019, at 9:30 a.m. Eastern Time at the Westin Grand Central Hotel. Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

    • Here's Why Profile Systems & Software A.E (ATH:PROF) Can Manage Its Debt Responsibly
      Simply Wall St.

      Here's Why Profile Systems & Software A.E (ATH:PROF) Can Manage Its Debt Responsibly

      Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

    • Taking A Look At Profile Systems  Software A.E.'s (ATH:PROF) ROE
      Simply Wall St.

      Taking A Look At Profile Systems Software A.E.'s (ATH:PROF) ROE

      One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

    • How Do Analysts See Profile Systems & Software A.E. (ATH:PROF) Performing In The Next Couple Of Years?
      Simply Wall St.

      How Do Analysts See Profile Systems & Software A.E. (ATH:PROF) Performing In The Next Couple Of Years?

      In April 2019, Profile Systems & Software A.E. (ATH:PROF) announced its latest earnings update, which showed that the...